Get Your Own businessabc Wiki
Boost credibility, visibility, and discoverability
Galmed was founded in 2000 and is headquartered in Tel Aviv, Israel. In 2008, the company entered into a collaboration agreement with Nestlé Health Science to study the potential of ARGAMAN, a novel derivative of omega-3 fatty acids (EFAs) for the treatment of NAFLD. The company thereafter initiated a Phase 2 proof-of-concept study in 2009 in order to test the safety and efficacy of ARGAMAN in subjects with NAFLD. This study subsequently led to the development of Aramchol, an oral therapy for the treatment of fatty liver associated with NASH.
